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a b s t r a c t
Aim: The aim of our study was the dosimetric and physical evaluation of the CK and IMRT
treatment plans for 16 patients with localized prostate cancer.
Background: Intensity modulated radiation therapy (IMRT) is one of the recent technical
advances in radiotherapy. The prostate is a well suited site to be treated with IMRT. The
challenge of accurately delivering the IMRT needs to be supported by new advances such
as image-guidance and four-dimensional computed conformal radiation therapy (4DCRT)
tomography. CyberKnife (CK) provides real time orthogonal X-ray imaging of the patient dur-
ing treatment course to followgoldﬁducials installed into theprostate and to achievemotion
correlation between online acquired X-ray imaging and digital reconstructed radiographs
(DRRs) which are obtained from planning computed tomography images by translating and
rotating the treatment table in ﬁve directions.
Methods andmaterials: Sixteen IMRTandCKplanswere performed to be compared in terms of
conformity (CI), heterogeneity indices (HI), percentage doses of 100% (V100), 66% (V66), 50%
(V50), 33% (V33) and 10% (V10) volumes of the bladder and rectum. Dose-volume histograms
for target and critical organs, (CI) and indices (HI) and isodose lineswere analyzed to evaluate
the treatment plans.
Results: Statistically signiﬁcant differences in the percentage rectal doses delivered to V10,
V33, and V50 of the rectum were detected in favor of the CK plans (p values; <0.001, <0.001
and 0.019, respectively). The percentage doses for V66 and V100 of the rectum were larger in
CK plans (13%, 2% in IMRT and 21%, 3% in CK plans, respectively). Percentage bladder doses
for V10 and V33 were signiﬁcantly lower in CK plans [96% in IMRT vs 48% in CK (p<0.001)
and 34% in IMRT vs 24% in CK (p=0.047)]. Lower percentage doses were observed for V50,
V66 of the bladder for the IMRT. They were 5.4% and 3.45% for IMRT and 13.4% and 8.05%
for CK, respectively. Median CI of planning target volume (PTV) for IMRT and CK plans were0.94 and 1.23, respectively (p<0.001).
Conclusion: Both systems have a very good ability to create highly conformal volumetric
dose distributions. Median
(p<0.001).
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1. Introduction
Intensity modulated radiation therapy (IMRT) is one of the
recent technical advances in radiotherapy. IMRT is an exten-
sion of three-dimensional radiation therapy (3DCRT) that uses
all the components of 3DCRT such as dose-volumehistograms
(DVHs) and target-normal tissue prescriptions. IMRT provides
better conformal dose shape especially in cases with concave
tumors using intensity modulated ﬁelds. Many studies have
reported that IMRT was superior to 3DCRT especially in head
and neck, prostate and cervical cancer cases.1–6
The prostate is a well suited treatment site to use IMRT.
IMRT has been proved to be an effective treatment tech-
nique for prostate cancer due to its improved target dose
while avoiding doses to the bladder and rectum. Compared
to 3DCRT, IMRT signiﬁcantly reduces late and acute toxicities
of radiotherapy and allows prostate dose escalation.7–9 Zelef-
sky et al.10 published the results of 772 prostate patients who
were treated with IMRT and reported that IMRT increased the
tumor control probability while decreasing complication rates
in normal structures.
Although IMRT represents better tumor control probability,
because of its complexity, it needs further quality assurance
program to ensure coincidence of planned and the deliv-
ered dose.11 Patient set-up errors, systematic errors and organ
motions during a treatment course may also reduce the suc-
cess of IMRT. Organ movements may lead to displacement
of the target to indented low isodose lines while organs at
risk may be in the high dose region. Numerous reports have
been published showing that prostatemovements and clinical
uncertainties for prostate IMRT must be realistically assessed
by the margins of planning target volume (PTV) and displace-
ments of the ﬁducials inserted to the prostate with daily
portal imaging.12–14 The challenge of accurately delivering
IMRTneeds to be supported by facilities such as Image-Guided
Radiotherapy (IGRT), four-dimensional conformal radiation
therapy (4DCRT) or CyberKnife (CK) robotic radiotherapy.
Aubin et al.15 have shown that gold marker seeds can be
placed into the prostate for routine daily imaging by Elec-
tronic Portal Imaging (EPID) device and can increase accuracy
of treatment. Although daily ultrasound-based imaging to
deﬁne prostate localization can improve the precision of IMRT
for prostate cancer cases, application of the technique needs
physician participation in each treatment.
However, CKprovides real timeorthogonalX-ray imagingof
the patient during a treatment course to follow gold ﬁducials
inserted into the prostate and movement correlation compar-
ing on-line acquired X-ray imaging and digital reconstructed
radiographs (DRRs) which are obtained from planning com-
puted tomography (CT) images by translating and rotating the
treatment table in ﬁve directions. These capabilities of CK
enable us to treat prostate cancer with less than 1mm accu-
racy. It therefore can allow us to reduce the margins of target
so that the incidental doses at the bladder and rectum are
minimized.CK is a frameless whole-body image guided robotic radio-
surgery system that has a 6MV linear accelerator mounted on
a computer controlled robotic arm and an orthogonal pair of
diagnostic X-ray imaging devices (see Fig. 1). CK can irradiateFig. 1 – CK robotic radiosurgery system.
the target using 1200 points in the room. It has the advantage
of delivering more doses to the target while avoiding doses to
normal structures.
In addition to dose escalation, hypo-fractionation might
also increase the therapeutic ratio due to low / of prostate
tumor cells. There have been many studies to investigate
hypo-fractionation for prostate cancer showing that large
doses per fraction allow to achieve the same or even better
tumor control while maintaining the same level of normal
tissue late effects and acute toxicity.16,17
Clinical policy in our center for localized prostate cancer
treatment with CK is to administer 36.25Gy in ﬁve fractions
with amean duration of session of 1.5–2h.When IMRT is used,
patients are treated to a total dose of 72–74Gy with 2Gy per
fraction in 35–37 fractions.
The aim of our current study is to evaluate dosimetric and
physical aspects of CK and IMRT treatment plans for localized
prostate cancer. DVHs for target and critical organs, confor-
mity index (CI), heterogeneity index (HI) and isodose lines
were employed to evaluate the treatment plans with retro-
spectively prepared IMRT and CK plans for sixteen patients
with localized prostate cancer.
2. Materials and methods
2.1. Patients and imaging
Sixteen patients with localized prostate cancer staged T1–T2
according to the TNM classiﬁcation 2002 (TNM Classiﬁcation
of Malignant Tumors) were included in our study.18 Median
age of the patients was 72. Thirteen of the selected patients
were treated with IMRT and other 3 patients were treated with
CK in our center. According to our clinical policy, as explained
in the section IMRT and CK plans below, IMRT and CK plans
were prepared for sixteen patients who were treated in our
clinic with CK or IMRT.
Patients were immobilized using an alpha cradle at a
supine position with full bladder for IMRT. CT scans from
the ﬁfth lumbar vertebrae level to 10 cm below the ischial
tuberosities in 3mm slice thickness were performed on a
ﬂat couch. After CT scan, magnetic resonance (MR) scanning
was performed to acquire T2-weighted imaging in 3mm slice
thickness to delineate the prostate and regions of interest
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Fig. 2 – (a) Delineated ROI’ IMRT plan; bladder (brown), cyan
(GTV), CTV (red), PTV (yellow), rectum (green), femoral
heads (blue). (b) Delineated ROI’ CyberKnife. (For
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ROI) accurately. CT and MR images were transferred to a vir-
ual simulation program to delineate regions of interest. Our
irtual simulation program (FocalSim, Computed Medical Sys-
em, St. Louis) is capable of fusingCTandMR images byMutual
nformation (MI).
Experienced radiation oncologist delineated the prostate
s a target and the bladder, rectum, femoral heads as critical
tructures using CT and MR fusion. The following ROIs were
eﬁned: Gross Tumor Volume (GTV) consisted of the prostate
ithout margin; Clinical Target Volume (CTV) included the
rimary GTV with 1 cm margin in all directions except pos-
erior direction. A margin of 0.5 cm was given from posterior
irection for CTV to reduce the rectum wall dose. In terms
f set-up errors and beam penumbra, PTV was created with
.5 cm for every direction and beams were conformed to PTV
ithout margin. Delineated CT images for all patients wereransferred to an inverse planning system (XiO, Computed
edical System, St. Louis) to generate IMRT plan. The delin-
ated structures for IMRT and CK plans can be seen in Fig. 2(a)
nd (b).Fig. 3 – Beam placement of IMRT plan on the XIO.
AlthoughCKhas its own imagingprotocol for the treatment
of localized prostate cancer,19 CT and MR data sets, which
were obtained for IMRT, were used to delineate structures for
the CK inverse planning system to obtain same volumes of
ROIs. CK treatment includes real time image guidance for all
treatment sites suchas skull tracking for head, implantedﬁdu-
cial tracking for prostate and spine cases. At least a week
before the treatment, gold seeds are implanted to prostate
by radiologists, 1mm slice thickness CT and MR images are
acquired in a supine position with alpha cradle. Generally, a
foley catheter is placed and the balloon ﬁlled with contrast
medium to outline the urethra.
A experienced radiation oncologist, who delineated the
structures for IMRT plans, delineated ROIs on fused CT andMR
images on the CK contouring computer (Cyris Inview, Accu-
ray, Sunnyvale, CA). CK allows delivery and tracking with a
precision of less than 1mm error. The target coverage within
the prescribed isodose at CK plan was within 3–5mm from
the contoured target. After deﬁnition of GTVs without margin
to the prostate, PTVs were created automatically with 0.5 cm
margin to GTV in all directions.
2.2. IMRT and CK plans
IMRT plans for 16 patients were generated using the CMS
XiO planning system for a 6MV linear accelerator (Siemens
Medical Solution, Conrad) with 41 pairs Multileaf Collimator
(MLC) using the step and shoot technique. All IMRT plans, with
one exception, were developed using a ﬁve-ﬁeld arrangement
including anterior (0◦), left anterior oblique (72◦), left posterior
oblique (144◦), right posterior oblique (216◦) and right anterior
oblique (288◦) ﬁelds. In only one patient, plan was done by
placing the beams starting from the posterior of the patient
(180◦) due to the patient’s anatomy. Fig. 3 shows the beam ori-
entation of a sample IMRT plan. The beams were placed at the
center of the PTV and conformed PTV to minimize penumbra
effect around the PTV. Inverse planning using a convolution
calculation algorithm was used to minimize a physical objec-
tive of the function between the calculation and prescribed
dose values in the target volume, as well as tolerance dose
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Table 1 – IMRT plan dose prescription of PTV, bladder, rectum and femoral heads.
Structure Type Rank Objective Dose (cGy) Volume (%) Weight Power
PTV Target 1 Max 7550 0 100 2.4
Min 7474 100 200 2.9
Bladder OAR 2 Dose volume 5000 25 100 2
Dose volume 3100 50 100
Rectum OAR 3 Dose volume 5000 17 100 2
Dose volume 3100 35 100
Right femoral heads OAR 4 Max 5000 0 100 2
Left femoral heads OAR 4 Max 5000 0 100 2
Patient OAR 5 Max 4500 0 100 2
Table 2 – An accepted IMRT plan index PTV and OAR’s according to deﬁned criteria.








Max Dose (Gy): 79.40 77.45 78.44 39.21 39.42 79.40 67
Min Dose (Gy): 71.96 0.52 1.11
Mean ose (Gy): 75.63 20.12 25.92
CI: 0.97a >70GyV7% >70GyV7%
HI: 0.91b
ical organs. Due to the steep dose gradient, we did not
deﬁne doses to femoral heads. Maximum dose, minimum
70% isodose coverage to PTV, beamlet numbers and treat-
ment time were taken into consideration during evaluation
Table 3 – The CyberKnife plan dose prescription index.
Structure Type Objectivea CI: conformity index of plans according to Eq. (1).
b HI: homogeneity index of plans according to Eq. (2).
values for critical structures.
Pollack et al.20 and Zelefsky et al.21 published articles
including large numbers of patients and showing that IMRT
treatment with >74Gy in patients with PSA>10ng/mL signif-
icantly improved the freedom from failure (FFF) time while
decreasing the rectal reactions. Our protocol was designed to
reach a total dose of 74Gy to the PTV in 37 fractions with 2Gy
per fraction. The dose distributionwas gained according to the
prescription of ROIs as shown in Table 1.
Plan acceptability was considered by comparing dose vol-
ume valueswith deﬁneddose values for PTV andOARs. Table 2
shows an accepted IMRT plan that maximum dose of femoral
heads under 50Gy, maximum dose of plan under 110% of pre-
scribed dose. Our planning system can generate segments
using discretization of the ideal intensity map. We limited
the number of discrete levels of segmentation to obtain a
reasonable subﬁeld number; otherwise it leads to longer treat-
ment times. Segment numbers of plans were generally kept
under 70 to keep the treatment time per fraction at about
18min. The segment number of an accepted plan was 67 as
shown in Table 2. Because of the step and shoot technique, the
treatment time covers “beam on” time and MLC movements
between segments.22,23
During evaluation of the plans, the dose distributions were
also investigated to ensure that there were no low dose region
within the CTV and no hotspots in uncontoured tissues. Our
radiation oncologist judged the plan according to clinical pol-
icy in some plans in which ideal dose distribution could not
be achieved because of the energy or patient anatomy. Conse-
quently, our plan evaluation criteria were the following:(1) 95% of PTVmust receive 74Gy and nomore than 5% of PTV
receives 105% of 74Gy.
(2) No more than 10% of the rectum and bladder volumes
receive more than 70Gy.(3) Maximum dose for femoral heads is 50Gy.
(4) The global maximum dose value of the plan must be less
than 110% of 74Gy.
(5) The hotspots of the plan must not overlap regions of the
rectum and bladder with PTV.
It was not always easy to achieve results such as bladder
and rectum doses ﬁtting to above mentioned criteria. There-
fore, we considered tolerance of the patient and followed the
toxicity of the treatment. In 8 plans, the bladder and rectum
volumes receiving >70Gy were larger than 10% of the volume.
CK plans were generated using the On-Target (Accuray,
Sunnyvale) planning system which uses a non-optimized
solution with a linear programming algorithm. Table 3 shows
prescription details of the CK plan. Median collimator size
for all treatment plans was 20mm. Since CK plans are gen-
erated as non-isocentric by inverse solution iterative process,
a physicist can assign individual ﬁne tuning to add or remove
doses of beams. Our current protocol is to prescribe a total
dose of 36.25Gy in 5 fractions (7.25Gy per fraction) to PTV
and maximum 32Gy to the bladder and rectum as crit-PTV Target Max Dose (cGy): 48
Min Dose: 36.25
Bladder OAR Max Dose (Gy): 32
Rectum OAR Max Dose (Gy): 32
Urethra OAR Max Dose (Gy): 41.69





















aFig. 4 – Treatment plan
f the plans. The maximum dose of uretha was deﬁned at
1–42Gy. Fig. 4 presents planning system of CK for a sample
atient.
The total planning time for IMRT was approximately 5h
ncluding image transfer, fusion of image sets, delineation
f ROIs, placement of beams, dose prescriptions and com-
uter calculation to ﬁnd the best solution. The veriﬁcation of
MRT plan should also be added to this time. Although there
re different methods and procedures that can be used,11
atient set-up accuracy of prostate cases is performed using
nline correction by correlationwith bony landmarks between
RRs and portal imaging taken every other day.24 Absolute
ose veriﬁcation of plans was done by ion chamber measure-
ents using an IMRT phantom (PTW Freiburg, Germany) and
elative dose distribution comparison on an array dosime-
er.
CK plans were generated in approximately 3–4h, includ-
ng all processes to ﬁnd an optimum plan without having
o check the plan individually for each patient. Therefore,
onthly and weekly quality assurances of CK consist of phan-
om treatment plans veriﬁcation to evaluate robot and linear
ccelerator performance. During treatment, CK is capable toen of the CyberKnife.
correct patient set-up in ﬁve dimensions, such as transla-
tions and rotations, by tracking at least 3 ﬁducials which
were pre-installed into patient’s prostate. The uncertainty of
tracking ﬁducials combines the effects of all errors originat-
ing from image guidance, indicating the accuracy of the robot
and the accuracy of target localization in treatment planning
process.
2.3. Comparison of treatment plans
Weprescribed themaximumPTVdose as 5%higher than 74Gy
and minimum PTV dose as 1% higher than 74Gy to achieve
95% coverage of PTV with 74Gy on IMRT plans, while keeping
the doses to the bladder and the rectum at the level exceeding
70Gy as ≤10%.
Fig. 6 presents a sample ﬁnal IMRTplan of a patient. Sixteen
IMRT and CK plans were performed for comparison in terms
of conformity (CI) and homogeneity indices (HI),25,26 and per-
centage doses of 100%, 66%, 50%, 33% and 10% volumes of the
bladder and rectum. These volumes were denoted as V100,
V66, V50, V33 and V10. No comparison was done for femoral
heads since doses at femoral heads were negligible.
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where VRI is the volume of prescribed dose for PTV, TV is the
total volume of PTV, Imax is the maximum dose and RI is the
prescribed dose of PTV. Differences were reported using Stu-
dent’s t-test with statistical signiﬁcance at the p<0.05 levels
(two tailed).
3. Results
CK and IMRT plans for 16 localized prostate patients were gen-
erated according to the clinical acceptable criteria to cover
PTV sufﬁciently. For the purpose of this study, we evaluated
plans with the consideration of physical and dosimetric com-
ponents of treatment without clinical inspection. As different
margins had been applied while creating CTV volume for both
IMRT and CK plans, different CTV volumes were obtained
for both plannings. Whereas median CTV volume for IMRT
plan was 132.5 cm3, 88.5 cm3 was found for the CK plan. Fig. 5
presents PTV volumes of patientswhichwere delineated IMRT
and CK plans with different margins
Figs. 6 and 7 show dose distributions of CK and IMRT for
the same patient. CK plans were normalized to median 75%
isodose lines to obtain 95% coverage of PTV. Dose distributions
Fig. 6 – IMRT planFig. 5 – PTV volumes of patients.
of the two plans reveal that CK has a higher dose gradient than
IMRT. The DVHs comparing IMRT and CK for the same patient
are shown in Fig. 7.
Table 4 shows statistical results of the two plans. The
median conformity indices of PTV for IMRT and CK plans were
0.94 and 1.23 (p<0.001), respectively. Both systems have a very
good ability to create highly conformal volumetric dose distri-
bution. We also compared the homogeneity of the two plans
and observed that the median homogeneity value of IMRT
plans is closer to 1 than CK plans into the target. The median
homogeneity indices of PTV for IMRTandCKplans are 1.08 and
1.33 (p<0.001), respectively. The inherent property of CK plan
is the heterogeneous dose distribution across the PTV. This
of the patient.
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Rectum (Cyberknife)Fig. 7 – DVH comparison of the Cy
roperty may enable us to modify the dose distribution within
TV and to intensify the dose especially in hypoxic regions.
For normal tissues, we evaluated the percentage doses of
0%, 33%, 50%, 66% and 100% volumes of the bladder and rec-
um in IMRT and CK plans. Signiﬁcant differences in the rectal
oses delivered to V10, V33, and V50 were observed in favor
f CK plans with p values of <0.001, <0.001 and 0.019, respec-
ively. The percentage doses for V66 and V100 of the rectum
ere larger for CK plans. They were 12.73% and 2.05% for IMRT
nd 20.95% and 2.60% for CK, respectively. Bladder doses for
10 and V33 were signiﬁcantly lower for CK plans. They were
6.25% and 33.75% for IMRT and 47.80% and 23.75% for CK,
espectively (p<0.001 and p=0.047, respectively). Lower per-
entage doses were observed for V50 and V66 of the bladder in
MRT. They were 5.4% and 3.45% for IMRT and 13.4% and 8.05%
or CK, respectively. Results of the analyses of all patients’ data
re shown in Fig. 8.
Table 4 – Median percent doses for bladder and rectum
volumes in all patients. V10, V33, V50, V66 and V100
denote percentage volumes of organs that 10%, 33%,
50%, 66% and 100% of volumes, respectively. Table
presents CI, HI and maximum and minimum doses for
PTV as a percent of prescription dose.
Median doses p Value
IMRT CK
%Bladder volume
V10 96.25% 47.80% <0.001
V33 33.75% 23.75% 0.047
V50 5.40% 13.40% 0.432
V66 3.45% 8.05% 0.198
V100 0.85% 0.10% 0.02
%Rectum volume
V10 96.30% 57.05% <0.001
V33 59.00% 35.10% <0.001
V50 38.48% 27.45% 0.019
V66 12.73% 20.95% 0.287
V100 2.05% 2.60% 0.049
PTV
CI 0.94 1.23 <0.001
HI 1.08 1.33 <0.001
Maximum percentage dose 108% 133%
Minimum percentage dose 95.30% 86%Fig. 8 – Bladder and rectum results for all patients.
4. Discussion
In our current study, we demonstrated the physical and dosi-
metric comparison of IMRT andCKplans for localized prostate
cancer. We evaluated the plans considering target coverage,
conformity and homogeneity indices, and the bladder and
rectum doses.
Our results indicated that the conformity andhomogeneity
of IMRT plans were better than CK plans. Although one of the
characteristics of IMRT is the ability to create a dose volume
with a very high conformity index, radiation doses to small
volumes of the bladder and rectum were higher than CK. CK
was superior to IMRT in protecting the rectum and bladder,
especially in high dose areas as shown in Fig. 8. Depending on
the nature of CK, beams reach the patient from 1200 points
around the patient. Larger volumes of the bladder and rectum
received low radiation dose in the CK plan. This should be
considered when total doses of the rectum and bladder are
calculated.
We observed that CK plans had inhomogeneous dose dis-
tributions compared to IMRT plans. The classical approach of
radiotherapy is to cover the PTV with prescribed dose while
keeping homogeneity within the PTV. However, some areas in
the prostate may require higher doses than other tumor con-
taining areas because of the hypoxic tumor sites. CK plans
have the advantage to give radiation dose into these areas
when hypoxic areas are deﬁned.
d rad
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Prostatemotionandmarginshavebeen investigated exten-
sively. Itwas shown that themarkedmovement of theprostate
is in the anterior-posterior direction.14,27,28 We used a 1 cm
margin for all directions, except posteriorwhichwas 0.5 cm for
PTV, and aimed to create an IMRT plan covering 95% of PTV by
prescribed dose while keeping account of prostate motion and
set-up errors. All IMRT patients were treated with full bladder
to minimize prostate motion and all patients treatment posi-
tion accuracies were evaluated with daily portal imaging by
bony structures superposed with DRR and portal imaging. We
did not use ﬁducials for IMRT patients. Therefore, increased
margins in IMRT plans could cause an increase of the vol-
ume of the bladder and rectum. PTV was created with 0.5 cm
margin in all directions for CK plan and we implemented 4
ﬁducials into the prostate to follow prostate motion during
treatment by taking on-line orthogonal X-ray images. Thus,
CK has the advantage for accurate target localization by real
time tracking and it can treat thepatientwith lower dose to the
bladder and rectum with reduced PTV margin. We show that
CK system has some advantage to treat early stage prostate
cancer andBindhuet al.29 conclude that aCK radiosurgery sys-
tem offers an invaluable solution to the treatment of selective
tumours/lesions located close to critical structures, salvage of
recurrent and metastatic lesions and potential of treatment
of selective early stage malignancies like the carcinoma of the
prostate and lung.
Despite the improved conformity with IMRT, the appli-
cation is limited by the treatment set-up, target movement
errors and long treatment days. The accurate delivery of
radiotherapy for prostate cancer needs involvement of IGRT,
4DCRT or CK. Although we did not focus on the radiobiology
of prostate cancer in our current study, there are several30
papers reporting that since the value of the / parameter for
prostate tumors is low, it may mean a high sensitivity to hypo-
fractionation. CK treatment protocol with hypo-fractionation
might yield high tumor control probability.
5. Conclusion
In the present study, we show that the difference in PTV
coverage between IMRT and CK plans is not very signiﬁcant.
Although the homogeneity index for IMRT plans is better than
CK plans, CK system could give opportunity to evaluate the
homogeneity considering the high dose within the prostate
gland. We concluded that CK has many attributes that allow
prostate treatment to be delivered very accurately and it can
be an alternative to treat prostate efﬁciently. In our hospi-
tal, we currently perform IMRT and CK treatments for early
stage localized prostate cancer and we plan to publish results
of these treatments to compare them with other treatment
options in terms of PSA level and side effects.
e f e r enc e s1. Ashman Jonathan B, Zelefsky Micheal J, Hunt Margie S,
Leibel Steven A, Fuks Zvi. Whole pelvic radiotherapy for
prostate cancer using 3D conformal andiotherapy 1 5 ( 2 0 1 0 ) 181–189
intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys
2005;63(3):765–71.
2. Luxton Gary, Hancock Steven L, Boyer Arthur L. Dosimetry
and radiobiological model comparison of IMRT and 3D
conformal radiotherapy in treatment of carcinoma of the
prostate. Int J Radiat Oncol Biol Phys 2004;59(1):267–84.
3. Vlachaki Maria T, Teslow Terrance N, Amosson Chad, Uy
Nathan W, Ahmad Salahuddin. IMRT versus conventional
3DCRT on prostate and normal tissue dosimetry using an
endorectal balloon for prostate immobilization. Med Dosim
2005;30(2):69–75.
4. James HV, Scrase CD, Poynter AJ. Practical experience with
intensity-modulated radiotherapy. Br J Radiol 2004;77:3–14.
5. Kara Bucci M, Bevan Alison, Roach III Mack. Advances in
radiation therapy: conventional to 3D, to IMRT, to 4D, and
beyond. CA Cancer J Clin 2005;55:117–34.
6. van de Bunt Linda, Van der Heide Uulke A, Ketelaars
Martijn, de Kort Gerard AP, Jürgenliemk-Schulz Ina M.
Conventional, conformal, and intensity-modulated
radiation therapy treatment planning of external beam
radiotherapy for cervical cancer: the impact of tumor
regression. Int J Radiat Oncol Biol Phys 2006;64(1):189–96.
7. De Meerleer Gert, Vakaet Luc, Meersschout Sabine, Villeirs
Gert, Verbaeys Antony, Oosterlinck Wim, et al. Intensity
modulated radiotherapy as primary treatment for prostate
cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol
Phys 2004;60(3):777–87.
8. De Meerleer Gert, Vakaet Luc, De Gersem Werner RT, De
Wagter Carlos, De Naeyer Bart, De Neve Wilfried.
Radiotherapy of prostate cancer with or without intensity
modulated beams: a planning comparison. Int J Radiat Oncol
Biol Phys 2000;47(3):639–48.
9. Sethi Anil, Mohideen Najeeb, Leybovich Leonid, Mulhall
John. Role of IMRT in reducing doses in dose escalation for
prostate cancer. Int J Radiat Oncol Biol Phys 2003;55(4):970–8.
10. Zelefsky Micheal J, Fuks Zvi, Happertsett Laura, Lee Henry J,
Ling C Clifton, Burman Chandra M, et al. Clinical experience
with intensity modulated radiation therapy (IMRT) in
prostate cancer. Radiat Oncol 2000;5:241–9.
11. Ezzell Gary A, Galvin James M, Low Daniel, Palta Jatinder R,
Rosen Isaac, Sharpe Michael B, et al. Guidance document on
delivery, treatment planning, and clinical implementation of
IMRT: report of the IMRT subcommittee of the AAPM
radiation therapy committee. Med Phys 2003;30(8):2089–115.
12. Boehmer Dirk, Maingon Philippe, Poortmans Philip, Baron
Marie-Hélène, Miralbell Raymond, Remouchamps Vincent,
et al. Guidelines for primary radiotherapy of patients with
prostate cancer. Radiat Oncol 2006;79:259–69.
13. Jones Andrew O, Kleiman Marc T. Patient setup and
veriﬁcation for intensity-modulated radiation therapy
(IMRT). Med Dosim 2003;28(3):175–83.
14. Nederveen AJ, van der Heide UA, Dehnad H, van Moorselaar
RJ, Hofman P, Lagendijk JJ. Measurements and clinical
consequences of prostate motion during a radiotherapy
fraction. Int J Radiat Oncol Biol Phys 2002;53:206–14.
15. Aubin M, Liu Y, Langen KM, Shinohara Katsuto, Anezinos
Chris, Osofsky Melanie, et al. Set-up veriﬁcation using portal
images of implanted markers: an inter-observer study. In
Abstract 44th annual ASTRO meeting, 2002.
16. Brenner David J. Hypofractionation for prostate cancer
radiotherapy—What are the issues? Int J Radiat Oncol Biol
Phys 2003;57(4):912–4.
17. Fowler F, Ritter MA, Chappell RJ, Brenner David J. What
hypofractionated protocols should be tested for prostate
cancer? Int J Radiat Oncol Biol Phys 2003;56:1093–2003.
18. Galvin James M, Ezzell Garyy, Eisbrauch Avraham, Yu Cedric,
Butler Brian, Xiao Ying, et al. Implementing IMRT in clinical
practice: a joint document of the American society for
radio
30. Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V,
Arcangeli G, et al. Phase II study of a four-weekreports of practical oncology and
therapeutic radiology and oncology and the American
association of physicists in medicine. Int J Radiat Oncol Biol
Phys 2004;58(5):1616–34.
19. Carlo Cavedon, Joseph Stancanello, Paolo Francescon,
Stefania Cora, Paolo Scalchi,Emanuela Berna, et al. Spelized
imaging techniques for cyberknife treatment planning. In
Robotic radiosurgery, vol. 1; 2005. p. 81–94 [chapter 9].
20. Pollack Alan, Zagars Gunar, Starkschall Gergo, Antolak John
A, Lee J Jack, Huang Eugene, et al. Prostate cancer radiation
dose response: results of the M.D. Anderson phase III
randomized trial. Int J Radiat Oncol Biol Phys
2002;53(5):1097–105.
21. Zelefsky Micheal J, Fuks Zvi, Hunt Margie, Yamada Yoshiya,
Marion Christine, Ling C Clifton, et al. High-dose intensity
modulated radiation therapy for prostate cancer: early
toxicity and biochemical outcome in 772 patients. Int J Radiat
Oncol Biol Phys 2002;53(5):1111–6.
22. Adams Elizabeth J, Convery David J, Cosgrove Vivian P, et al.,
McNair Helen A, Staffurth John N, Vaarkamp Jaap, et al.
Clinical implementation of dynamic and step-and-shoot
IMRT to treat prostate cancer with high risk of pelvic lymph
node involvement. Radiat Oncol 2004;70:1–10.
23. Livi Lorenzo, Paiar Fabiola, Banci-Buonamici Fabrizio,
Gabriele Simontacchi, Beatrice Detti, Mauro Gacci, et al.
Localized prostate cancer treated with intensity-modulated
radiotherapy. Tumori 2006;92:201–6.
24. Melian Edward, Mageras Gig S, Fuks Zvi, Leibel Steven A,
Niehaus Anita, Lorant Helen, et al. Variation in prostatetherapy 1 5 ( 2 0 1 0 ) 181–189 189
position quantitation and implications for
three-dimensional conformal treatment planning. Int J
Radiat Oncol Biol Phys 1997;38(1):73–81.
25. Wu Vincent WC, Kwong Dora LW, Sham Jonathan ST. Target
dose conformity in 3-dimensional conformal radiotherapy
and intensity modulated radiotherapy. Radiat Oncol
2004;71:201–6.
26. Feuvret Loic, Noel Georges, Mazeron Jean-Jacques, Bey
Pierre. Conformity index: a review. Int J Radiat Oncol Biol Phys
2006;64(2):333–42.
27. Teh Bin S, Bastach Micheal D, Wheeler Thomas M, Maiet
Wei-Yuan, Frolov Anna, Uhl Barry M, et al. IMRT for prostate
cancer: deﬁning target volume based on correlated
pathologic volume of disease. Int J Radiat Oncol Biol Phys
2003;56(1):184–91.
28. Brenner David J, Hall Eric J. Fractionation and protraction for
radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol
Phys 1999;43(5):1095–101.
29. Bindhu J, Supe Sanjay S, Ramachandra Aruna. Cyberknife: a
double edged sword? Rep Pract Oncol Radiother
2010;15(4):93–7.hypofractioned external beam radiotherapy regimen for
prostate cancer: report on acute toxicity. Radiother Oncol
2006;80:78–81.
